Immunogenicity of fractional-dose vaccine during a yellow fever outbreak — Final report

New England Journal of Medicine

Volumn 381, Issue 5, 2019, Pages 444-454

  Casey, Rebecca M ^a   Harris, Jennifer B ^a   Ahuka Mundeke, Steve ^b   Dixon, Meredith G ^a   Kizito, Gabriel M ^b   Nsele, Pierre M ^b   Umutesi, Grace ^a   Laven, Janeen ^f   Kosoy, Olga ^f   Paluku, Gilson ^a   Gueye, Abdou S ^c   Hyde, Terri B ^a   Ewetola, Raimi ^d   Sheria, Guylain K M ^e   Muyembe Tamfum, Jean Jacques ^b   Staples, J Erin ^f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Institut National de Recherche Biomedicale   (Democratic Republic Congo)

^c Division of Global Health Protection   (Democratic Republic Congo)

^d CDC   (Democratic Republic Congo)

^e MINISTÈRE DE LA SANTÉ   (Democratic Republic Congo)

^f NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; ANGOLA; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; DEMOCRATIC REPUBLIC CONGO; EPIDEMIC; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; IMMUNE RESPONSE; MALE; MIDDLE AGED; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; SERODIAGNOSIS; VACCINATION; VACCINE IMMUNOGENICITY; YELLOW FEVER; YOUNG ADULT; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; MULTICENTER STUDY; YELLOW FEVER VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DEMOCRATIC REPUBLIC OF THE CONGO; DISEASE OUTBREAKS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SEROCONVERSION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 85070879317     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1710430     Document Type: Article

References (30)

1. Garske T, Van Kerkhove MD, Yactayo S, et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 2014;11(5):e1001638.
2. Staples JE, Monath TP, Gershman M, Barrett ADT. Yellow fever. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Vaccines. 7th ed. Philadelphia: Else-vier Saunders, 2018:1181-267.
3. Beck AS, Barrett AD. Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines 2015;14:1479-92.
4. Vaccines and vaccination against yellow fever: WHO position paper — June 2013. Wkly Epidemiol Rec 2013;88:269-83.
5. Staples JE, Bocchini JA Jr, Rubin L, Fischer M. Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:647-50.
6. Situation report: yellow fever, 28 October 2016. Geneva: World Health Organization (http://apps.who.int/iris/bitstream/10665/250661/1/yellowfeversitrep28Oct16 -eng.pdf?ua=1).
7. Update on progress controlling yellow fever in Africa, 2004-2008. Wkly Epidemiol Rec 2008;83:450-8.
8. Martins RM, Maia Mde L, Farias RH, et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother 2013;9: 879-88.
9. Campi-Azevedo AC, de Almeida Este-vam P, Coelho-Dos-Reis JG, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis 2014;14:391.
10. Lopes Ode S, Guimarães SS, de Car-valho R. Studies on yellow fever vaccine. III. Dose response in volunteers. J Biol Stand 1988;16:77-82.
11. Roukens AH, Gelinck LB, Visser LG. Intradermal vaccination to protect against yellow fever and influenza. Curr Top Mi-crobiol Immunol 2012;351:159-79.
12. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response: WHO Secretariat information paper. Geneva: World Health Organization, July 20, 2016 (http://apps.who.int/iris/ bitstream/10665/246236/1/WHO-YF-SAGE -16.1-eng.pdf?ua=1).
13. Yellow fever mass vaccination campaign using fractional dose in Kinshasa, DRC. Geneva: World Health Organization, September 26, 2016 (http://www.who.int/immunization/sage/meetings/2016/october/ 4_Yellow_fever_mass_vaccination _campaign_using_fractional_dose _in_Kinshasa.pdf?ua=1).
14. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 2016;65:1-54.
15. Fractional dosing of yellow fever vaccines: review of vaccine potency and stability information, available evidence, and evidence gaps. Presented at the Strategic Advisory Group of Experts (SAGE) meeting, Geneva, October 18–20, 2016 (http://www.who.int/immunization/sage/meetings/ 2016/october/presentations_background _docs/en/index1.html).
16. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. Geneva: World Health Organization, 2010 (http://www.who.int/biologicals/YF_Recommendations _post_ECBS_FINAL_rev_12_Nov_2010 .pdf).
17. Beaty BJ, Calisher CH, Shope RE. Arbo-viruses. In: Lennette EH, Lennette DA, Lennette ET, eds. Diagnostic procedures for viral, rickettsial and chlamydial infections. 7th ed. Washington, DC: American Public Health Association, 1995:189-212.
18. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005;23:5205-11.
19. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to Dengue viruses. Viral Immunol 2008;21: 123-32.
20. Epidemiological Update: Yellow Fever. Washington, DC: Pan American Health Organization, March 2018 (https://www.paho.org/hq/index.php?option=com_ docman&view=download&category_slug =yellow-fever-2194&alias=44111-20-march -2018-yellow-fever-epidemiological-update -111&Itemid=270&lang=en).
21. Immunization, vaccines and biologicals: data, statistics and graphics — WHO/UNICEF Estimates of National Immunization Coverage (WUENIC). Geneva: World Health Organization, 2017 (http://www.who.int/immunization/monitoring_surveillance/data/en/).
22. Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged virae-mia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 2011;6(12):e27753.
23. Niedrig M, Kürsteiner O, Herzog C, Sonnenberg K. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 2008;15:177-81.
24. Camacho LA, da Silva Freire M, da Luz Fernandes Leal M, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004;38:671-8.
25. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002;66:533-41.
26. de Menezes Martins R, Maia MLS, de Lima SMB, et al. Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine 2018;36:4112-7.
27. Roukens AHE, van Halem K, de Visser AW, Visser LG. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med 2018;169:761-5.
28. Yellow fever vaccine: WHO position on the use of fractional doses — June 2017. Wkly Epidemiol Rec 2017;92:345-50.
29. Nzolo D, Engo Biongo A, Kuemmerle A, et al. Safety profile of fractional dosing of the 17DD yellow fever vaccine among males and females: experience of a community-based pharmacovigilance in Kinshasa, DR Congo. Vaccine 2018;36:6170-82.
30. Breugelmans JG, Lewis RF, Agbenu E, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013;31:1819-29.